FASN and type 2 diabetes mellitus: Fgf21, encoding for Fibroblast growth factor 21, is currently being investigated as novel therapeutic agent for T2DM [34],[35], and the anti-diabetic properties of the fatty acid synthase (Fasn) inhibitor platensimycin have recently been demonstrated in a mouse model [36].